This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Elevance Health (ELV) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Elevance Health (ELV) concluded the recent trading session at $483.12, signifying a +0.76% move from its prior day's close.
Analyzing Cigna & Humana Merger Talks: Opportunities & Obstacles
by Kaibalya Pravo Dey
The Cigna-Humana merger will provide the combined body with increased negotiation power with healthcare providers, pharmaceutical companies and other stakeholders.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Here's Why Elevance Health (ELV) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Teladoc (TDOC) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals
by Zacks Equity Research
Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Top Stock Reports for Procter & Gamble, Novartis & Mondelez International
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novartis AG (NVS) and Mondelez International, Inc. (MDLZ).
Why Is Elevance Health (ELV) Up 0.1% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cigna (CI) Unit Unveils Pricing Model for Pharmacy Clients
by Zacks Equity Research
Cigna's (CI) sub-unit Express Scripts introduces a pricing option for prescription drugs that may bolster the customer base and fetch higher pharmacy revenues to the health insurer.
3 Reasons Why Growth Investors Shouldn't Overlook Elevance Health (ELV)
by Zacks Equity Research
Elevance Health (ELV) possesses solid growth attributes, which could help it handily outperform the market.
ELV or AMEH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. AMEH: Which Stock Is the Better Value Option?
Why Elevance Health (ELV) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tenet Healthcare (THC) Q3 Earnings Beat on Solid Ambulatory Care
by Zacks Equity Research
Tenet Healthcare's (THC) Q3 results gain on improved adjusted admissions and higher pricing yield. Management expects adjusted EPS of $5.43-$6.05 for 2023.
Encompass Health's (EHC) Q3 Earnings Beat on Discharge Growth
by Zacks Equity Research
Encompass Health's (EHC) Q3 results benefit from an increase in patient volumes and net patient revenue per discharge. Management currently projects adjusted EPS to be within $3.41-$3.52 for 2023.
ELV vs. HQY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. HQY: Which Stock Is the Better Value Option?
DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook
by Zacks Equity Research
DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.
West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect a strong demand for non-COVID-19 demand, especially HVP devices.
Wall Street Analysts Predict a 25.45% Upside in Elevance Health (ELV): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Elevance Health (ELV) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Teladoc Health (TDOC) Q3 Loss Narrows on Integrated Care Strength
by Zacks Equity Research
Teladoc Health's (TDOC) Q3 results were aided by membership growth in the Integrated Care unit as well as strong BetterHelp revenues. Management presently expects 2023 net loss per share to be within $1.50-$1.40.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Toyota Motor, Elevance Health, Illinois Tool Works, Ross Stores and Yum China
by Zacks Equity Research
Toyota Motor, Elevance Health, Illinois Tool Works, Ross Stores and Yum China are part of the Zacks top Analyst Blog.
Top Analyst Reports for Toyota Motor, Elevance Health & Illinois Tool Works
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Toyota Motor Corporation (TM), Elevance Health, Inc. (ELV) and Illinois Tool Works Inc. (ITW).